TapewireFind a company

person · Reporting owner

FONTEYNE PAUL R.

Disclosed activity across 7 companies

Tapewire entity
27194
SEC CIK
0001727550

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Adicet Bio, Inc.TORC · Entity 6860DirectorJune 03, 2020June 05, 2020
Amylyx Pharmaceuticals, Inc.AMLX · Entity 259DirectorJune 04, 2026June 08, 2026
Apnimed, Inc.APMD · Entity 4910DirectorJuly 30, 2026August 03, 2026
COVETRUS, INC.CVET · Entity 123087DirectorOctober 13, 2022October 13, 2022
GELESIS HOLDINGS, INC.GLS · Entity 109516DirectorMay 06, 2022May 09, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Adicet Bio, Inc.

Report date June 03, 2020 · Filed June 05, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.23 · Expires 2030-06-02Direct14,414 Reported balance After 2020-06-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2020-06-03 · Grant · Acquired 14,414 · Balance 14,414

F1: This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

Amylyx Pharmaceuticals, Inc.

Report date June 04, 2026 · Filed June 08, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.31 · Expires 2036-06-03Direct24,372 Reported balance After 2026-06-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-04 · Grant · Acquired 24,372 · Balance 24,372

F1: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Apnimed, Inc.

Report date July 30, 2026 · Filed August 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2033-09-18Direct0 Reported balance After 2026-08-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-08-03 · Disposition to issuer · Disposed 51,890 · Balance 0

F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 18, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2033-09-18Direct51,890 Reported balance After 2026-08-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-08-03 · Grant · Acquired 51,890 · Balance 51,890

F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 18, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-07-07Direct0 Reported balance After 2026-08-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-08-03 · Disposition to issuer · Disposed 44,477 · Balance 0

F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-07-07Direct44,477 Reported balance After 2026-08-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-08-03 · Grant · Acquired 44,477 · Balance 44,477

F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29Direct44,477 Reported balance After 2026-07-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-07-30 · Grant · Acquired 44,477 · Balance 44,477

F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29Direct0 Reported balance After 2026-08-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-08-03 · Disposition to issuer · Disposed 44,477 · Balance 0

F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29Direct44,477 Reported balance After 2026-08-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-08-03 · Grant · Acquired 44,477 · Balance 44,477

F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 18, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

COVETRUS, INC.

Report date October 13, 2022 · Filed October 13, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2022-10-13 transaction · row 1
1 source row

Row 1 · 2022-10-13 · Disposition to issuer · Disposed 13,275 · Balance 0

F1: In connection with the merger of Corgi Merger Sub, Inc. ("Merger Sub") with and into the Issuer (the "Merger") pursuant to that certain Agreement and Plan of Merger, dated as of May 24, 2022, as amended from time to time, by and among the Issuer, Corgi Bidco, Inc. and Merger Sub, Inc. ("Merger Agreement"), shares of common stock, par value $0.01 per share, of the Issuer (the "Shares" and each a "Share"), were converted into the right to receive $21.00 per Share in cash, without interest (the "Merger Consideration").

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-10-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2022-10-13 · Disposition to issuer · Disposed 14,638 · Balance 0

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.

F3: Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the merger of Corgi Merger Sub, Inc. ("Merger Sub") with and into the Issuer (the "Merger") pursuant to that certain Agreement and Plan of Merger, dated as of May 24, 2022, as amended from time to time, by and among the Issuer, Corgi Bidco, Inc. and Merger Sub, Inc. ("Merger Agreement"), shares of common stock, par value $0.01 per share, of the Issuer (the "Shares" and each a "Share"), were converted into the right to receive $21.00 per Share in cash, without interest (the "Merger Consideration").

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.

F3: Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration.

GELESIS HOLDINGS, INC.

Report date May 06, 2022 · Filed May 09, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect53,832 Reported balance After 2022-05-06 transaction · row 1
1 source row

Row 1 · 2022-05-06 · Grant · Acquired 53,832 · Balance 53,832

F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement.

F2: These RSUs vest in full on March 3, 2023, subject to the reporting person's continued service at such time.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement.

F2: These RSUs vest in full on March 3, 2023, subject to the reporting person's continued service at such time.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMAG PHARMACEUTICALS, INC.

Report date November 16, 2020 · Filed November 17, 2020

Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2020-11-16 transaction · row 1
1 source row

Row 1 · 2020-11-16 · Disposition to issuer · Disposed 14,676 · Balance 0

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-11-16 · Disposition to issuer · Disposed 6,000 · Balance 0

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2020-11-16 · Disposition to issuer · Disposed 9,452 · Balance 0

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-11-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2020-11-16 · Disposition to issuer · Disposed 21,289 · Balance 0

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Apellis Pharmaceuticals, Inc.

Report date May 14, 2026 · Filed May 14, 2026

Section 16 reporting ended · disclosed 2026-05-14. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2026-05-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-05-14 · Other · Disposed 30,666 · Balance 0

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"),

F2: (continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions,

F3: (continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2026-05-14 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2026-05-14 · Disposition to issuer · Disposed 3,062 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2026-05-14 transaction · row 3 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 3 · 2026-05-14 · Disposition to issuer · Disposed 5,744 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2026-05-14 transaction · row 4 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 4 · 2026-05-14 · Disposition to issuer · Disposed 7,961 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2026-05-14 transaction · row 5 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 5 · 2026-05-14 · Disposition to issuer · Disposed 3,544 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2026-05-14 transaction · row 6 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 6 · 2026-05-14 · Disposition to issuer · Disposed 3,877 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.12Direct0 Reported balance After 2026-05-14 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-05-14 · Disposition to issuer · Disposed 14,684 · Balance 0

F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.13Direct0 Reported balance After 2026-05-14 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2026-05-14 · Disposition to issuer · Disposed 37,500 · Balance 0

F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.91Direct0 Reported balance After 2026-05-14 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2026-05-14 · Disposition to issuer · Disposed 11,199 · Balance 0

F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.28Direct0 Reported balance After 2026-05-14 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2026-05-14 · Disposition to issuer · Disposed 8,554 · Balance 0

F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.71Direct0 Reported balance After 2026-05-14 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2026-05-14 · Disposition to issuer · Disposed 7,441 · Balance 0

F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.20Direct0 Reported balance After 2026-05-14 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2026-05-14 · Disposition to issuer · Disposed 27,600 · Balance 0

F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.86Direct0 Reported balance After 2026-05-14 transaction · row 13 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 13 · 2026-05-14 · Disposition to issuer · Disposed 5,748 · Balance 0

F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"),

F2: (continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions,

F3: (continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes.

F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 03, 2026 Filed Aug 3, 2026 20:01 UTC Apnimed, Inc. APMD · Entity 4910 GrantStock Option (Right to Buy) · Derivative 44,477 $0.00 Strike: $16.00 $0.00
Disclosure

SEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 7

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,477

Underlying: Common Stock · 44,477 shares

Expires 2036-07-29

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
August 03, 2026 Filed Aug 3, 2026 20:01 UTC Apnimed, Inc. APMD · Entity 4910 Disposition to issuerStock Option (Right to Buy) · Derivative 44,477 $0.00 Strike: $16.00 $0.00
Disclosure

SEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 6

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 44,477 shares

Expires 2036-07-29

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
August 03, 2026 Filed Aug 3, 2026 20:01 UTC Apnimed, Inc. APMD · Entity 4910 GrantStock Option (Right to Buy) · Derivative 44,477 $0.00 Strike: $8.15 $0.00
Disclosure

SEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 4

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,477

Underlying: Common Stock · 44,477 shares

Expires 2036-07-07

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F3 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
August 03, 2026 Filed Aug 3, 2026 20:01 UTC Apnimed, Inc. APMD · Entity 4910 Disposition to issuerStock Option (Right to Buy) · Derivative 44,477 $0.00 Strike: $8.15 $0.00
Disclosure

SEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 3

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 44,477 shares

Expires 2036-07-07

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F3 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
August 03, 2026 Filed Aug 3, 2026 20:01 UTC Apnimed, Inc. APMD · Entity 4910 GrantStock Option (Right to Buy) · Derivative 51,890 $0.00 Strike: $4.00 $0.00
Disclosure

SEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 2

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,890

Underlying: Common Stock · 51,890 shares

Expires 2033-09-18

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 18, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
August 03, 2026 Filed Aug 3, 2026 20:01 UTC Apnimed, Inc. APMD · Entity 4910 Disposition to issuerStock Option (Right to Buy) · Derivative 51,890 $0.00 Strike: $4.00 $0.00
Disclosure

SEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 51,890 shares

Expires 2033-09-18

F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.

F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 18, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
July 30, 2026 Filed Aug 3, 2026 20:01 UTC Apnimed, Inc. APMD · Entity 4910 GrantStock Option (Right to Buy) · Derivative 44,477 $0.00 Strike: $16.00 $0.00
Disclosure

SEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 5

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,477

Underlying: Class A Common Stock · 44,477 shares

Expires 2036-07-29

F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:00 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (right to buy) · Derivative 24,372 $0.00 Strike: $14.31 $0.00
Disclosure

SEC source: 0001193125-26-261637 · ownership.xml · derivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,372

Underlying: Common Stock · 24,372 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Read SEC document
May 14, 2026 Filed May 14, 2026 23:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 Disposition to issuerStock Option (right to buy) · Derivative 5,748 Not disclosed Strike: $59.86 Not disclosed
Disclosure

SEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 13

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,748 shares

Expires not disclosed

F7 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

Read SEC document
May 14, 2026 Filed May 14, 2026 23:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 Disposition to issuerStock Option (right to buy) · Derivative 27,600 Not disclosed Strike: $57.20 Not disclosed
Disclosure

SEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 12

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,600 shares

Expires not disclosed

F7 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

Read SEC document
May 14, 2026 Filed May 14, 2026 23:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 Disposition to issuerStock Option (right to buy) · Derivative 7,441 Not disclosed Strike: $51.71 Not disclosed
Disclosure

SEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 11

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,441 shares

Expires not disclosed

F7 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

Read SEC document
May 14, 2026 Filed May 14, 2026 23:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 Disposition to issuerStock Option (right to buy) · Derivative 8,554 Not disclosed Strike: $47.28 Not disclosed
Disclosure

SEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 10

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,554 shares

Expires not disclosed

F7 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.

Read SEC document
May 14, 2026 Filed May 14, 2026 23:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 Disposition to issuerStock Option (right to buy) · Derivative 11,199 Not disclosed Strike: $31.91 Not disclosed
Disclosure

SEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 9

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,199 shares

Expires not disclosed

F6 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

Read SEC document
May 14, 2026 Filed May 14, 2026 23:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 Disposition to issuerStock Option (right to buy) · Derivative 37,500 Not disclosed Strike: $26.13 Not disclosed
Disclosure

SEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 8

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,500 shares

Expires not disclosed

F6 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

Read SEC document
May 14, 2026 Filed May 14, 2026 23:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 Disposition to issuerStock Option (right to buy) · Derivative 14,684 Not disclosed Strike: $25.12 Not disclosed
Disclosure

SEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 7

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,684 shares

Expires not disclosed

F6 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.

Read SEC document
May 14, 2026 Filed May 14, 2026 23:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 Disposition to issuerCommon Stock 3,877 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-224618 · ownership.xml · nonDerivative · entry 6

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5 · price: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

F4 · balance_after: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5 · balance_after: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

Read SEC document
May 14, 2026 Filed May 14, 2026 23:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 Disposition to issuerCommon Stock 3,544 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-224618 · ownership.xml · nonDerivative · entry 5

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5 · price: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

F4 · balance_after: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5 · balance_after: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

Read SEC document
May 14, 2026 Filed May 14, 2026 23:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 Disposition to issuerCommon Stock 7,961 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-224618 · ownership.xml · nonDerivative · entry 4

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5 · price: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

F4 · balance_after: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5 · balance_after: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

Read SEC document
May 14, 2026 Filed May 14, 2026 23:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 Disposition to issuerCommon Stock 5,744 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-224618 · ownership.xml · nonDerivative · entry 3

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5 · price: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

F4 · balance_after: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5 · balance_after: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

Read SEC document
May 14, 2026 Filed May 14, 2026 23:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 Disposition to issuerCommon Stock 3,062 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-224618 · ownership.xml · nonDerivative · entry 2

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5 · price: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

F4 · balance_after: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.

F5 · balance_after: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.

Read SEC document
May 14, 2026 Filed May 14, 2026 23:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 OtherCommon Stock 30,666 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-224618 · ownership.xml · nonDerivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"),

F2 · kind: (continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions,

F3 · kind: (continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes.

F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"),

F2 · price: (continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions,

F3 · price: (continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes.

Read SEC document
January 01, 2026 Filed Jan 5, 2026 21:36 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 GrantStock Option (Right to Buy) · Derivative 14,684 $0.00 Strike: $25.12 $0.00
Disclosure

SEC source: 0001492422-26-000010 · form4.xml · derivative · entry 2

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,684

Underlying: Common Stock · 14,684 shares

Expires 2033-12-31

F2 · derivative.exercise_date: This option was granted on January 1, 2026. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant.

Read SEC document
January 01, 2026 Filed Jan 5, 2026 21:36 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 GrantCommon Stock 7,961 $0.00 $0.00
Disclosure

SEC source: 0001492422-26-000010 · form4.xml · nonDerivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,666

F1 · kind: This restricted stock unit was granted on January 1, 2026. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.

Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:12 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $5.05 $0.00
Disclosure

SEC source: 0000950170-25-083734 · ownership.xml · derivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Read SEC document
January 01, 2025 Filed Jan 3, 2025 21:19 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 GrantStock Option (Right to Buy) · Derivative 11,199 $0.00 Strike: $31.91 $0.00
Disclosure

SEC source: 0001127602-25-000425 · form4.xml · derivative · entry 2

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,199

Underlying: Common Stock · 11,199 shares

Expires 2032-12-31

F2 · derivative.exercise_date: This option was granted on January 1, 2025. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant.

Read SEC document
January 01, 2025 Filed Jan 3, 2025 21:19 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 GrantCommon Stock 6,267 $0.00 $0.00
Disclosure

SEC source: 0001127602-25-000425 · form4.xml · nonDerivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,705

F1 · kind: This restricted stock unit was granted on January 1, 2025. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.

Read SEC document
June 06, 2024 Filed Jun 7, 2024 20:52 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $1.76 $0.00
Disclosure

SEC source: 0000950170-24-070811 · ownership.xml · derivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 6, 2025 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Read SEC document
January 01, 2024 Filed Jan 2, 2024 21:13 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 GrantStock Option (Right to Buy) · Derivative 5,748 $59.86 Strike: $59.86 $344,075.28
Disclosure

SEC source: 0001127602-24-000120 · form4.xml · derivative · entry 2

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,748

Underlying: Common Stock · 5,748 shares

Expires 2030-12-31

F2 · derivative.exercise_date: This option was granted on January 1, 2024. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant.

Read SEC document
January 01, 2024 Filed Jan 2, 2024 21:13 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 GrantCommon Stock 3,341 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-000120 · form4.xml · nonDerivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,438

F1 · kind: This restricted stock unit was granted on January 1, 2024. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.

Read SEC document
June 08, 2023 Filed Jun 12, 2023 23:34 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (right to buy) · Derivative 16,985 $0.00 Strike: $26.25 $0.00
Disclosure

SEC source: 0000899243-23-015406 · doc4.xml · derivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,985

Underlying: Common Stock · 16,985 shares

Expires 2033-06-08

F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 8, 2024 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Read SEC document
January 01, 2023 Filed Jan 4, 2023 22:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 GrantStock Option (Right to Buy) · Derivative 7,441 $0.00 Strike: $51.71 $0.00
Disclosure

SEC source: 0000899243-23-000668 · doc4.xml · derivative · entry 2

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,441

Underlying: Common Stock · 7,441 shares

Expires 2030-12-31

F2 · derivative.exercise_date: This option was granted on January 1, 2023. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant.

Read SEC document
January 01, 2023 Filed Jan 4, 2023 22:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 GrantCommon Stock 3,867 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-000668 · doc4.xml · nonDerivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,097

F1 · kind: This restricted stock unit was granted on January 1, 2023. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.

Read SEC document
October 13, 2022 Filed Oct 13, 2022 15:03 UTC COVETRUS, INC. CVET · Entity 123087 Disposition to issuerRestricted Stock Units · Derivative 14,638 $0.00 $0.00
Disclosure

SEC source: 0001752836-22-000143 · wf-form4_166567340597921.xml · derivative · entry 2

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,638 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration.

F3 · derivative.expiration_date: Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration.

Read SEC document
October 13, 2022 Filed Oct 13, 2022 15:03 UTC COVETRUS, INC. CVET · Entity 123087 Disposition to issuerCommon Stock 13,275 $0.00 $0.00
Disclosure

SEC source: 0001752836-22-000143 · wf-form4_166567340597921.xml · nonDerivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: In connection with the merger of Corgi Merger Sub, Inc. ("Merger Sub") with and into the Issuer (the "Merger") pursuant to that certain Agreement and Plan of Merger, dated as of May 24, 2022, as amended from time to time, by and among the Issuer, Corgi Bidco, Inc. and Merger Sub, Inc. ("Merger Agreement"), shares of common stock, par value $0.01 per share, of the Issuer (the "Shares" and each a "Share"), were converted into the right to receive $21.00 per Share in cash, without interest (the "Merger Consideration").

Read SEC document
July 01, 2022 Filed Jul 6, 2022 20:06 UTC COVETRUS, INC. CVET · Entity 123087 Exercise / conversionRestricted Stock Units · Derivative 8,275 $0.00 $0.00
Disclosure

SEC source: 0001752836-22-000098 · wf-form4_165713799617599.xml · derivative · entry 2

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,275 shares

Expires 2022-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.

F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date.

Read SEC document
July 01, 2022 Filed Jul 6, 2022 20:06 UTC COVETRUS, INC. CVET · Entity 123087 Exercise / conversionCommon Stock 8,275 $0.00 $0.00
Disclosure

SEC source: 0001752836-22-000098 · wf-form4_165713799617599.xml · nonDerivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,275

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 09, 2022 Filed Jun 10, 2022 20:05 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (Right to Buy) · Derivative 19,000 $0.00 Strike: $13.56 $0.00
Disclosure

SEC source: 0000899243-22-021890 · doc4.xml · derivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2032-06-09

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director.

Read SEC document
May 11, 2022 Filed May 13, 2022 20:10 UTC COVETRUS, INC. CVET · Entity 123087 GrantRestricted Stock Units · Derivative 14,638 $0.00 $0.00
Disclosure

SEC source: 0001752836-22-000071 · wf-form4_165247260944118.xml · derivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,638

Underlying: Common Stock · 14,638 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.

F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date.

F2 · derivative.expiration_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date.

Read SEC document
May 06, 2022 Filed May 9, 2022 16:17 UTC GELESIS HOLDINGS, INC. GLS · Entity 109516 GrantCommon Stock 53,832 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-22-057532 · tm2214815d6_4seq1.xml · nonDerivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,832

F1 · kind: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement.

F2 · shares: These RSUs vest in full on March 3, 2023, subject to the reporting person's continued service at such time.

F1 · price: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement.

Read SEC document
January 06, 2022 Filed Jan 11, 2022 01:37 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 GrantStock Option (Right to Buy) · Derivative 8,400 $0.00 Strike: $19.00 $0.00
Disclosure

SEC source: 0000899243-22-001527 · doc4.xml · derivative · entry 2

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,400

Underlying: Common Stock · 8,400 shares

Expires 2032-01-06

F1 · derivative.exercise_date: This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Read SEC document
January 06, 2022 Filed Jan 11, 2022 01:37 UTC Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 PurchaseCommon Stock 3,947 $19.00 $74,993.00
Disclosure

SEC source: 0000899243-22-001527 · doc4.xml · nonDerivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,947

Read SEC document
January 01, 2022 Filed Jan 5, 2022 02:28 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 GrantStock Option (Right to Buy) · Derivative 8,554 $0.00 Strike: $47.28 $0.00
Disclosure

SEC source: 0001127602-22-000726 · form4.xml · derivative · entry 2

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,554

Underlying: Common Stock · 8,554 shares

Expires 2029-12-31

F2 · derivative.exercise_date: This represents a non-qualified stock option grant made on 1/1/2022 that vests quarterly over 1 year from the date of grant, subject to continued service as a director, and expires seven years from the date of grant.

Read SEC document
January 01, 2022 Filed Jan 5, 2022 02:28 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 GrantCommon Stock 4,230 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-000726 · form4.xml · nonDerivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,230

F1 · kind: This represents a restricted stock unit grant made on 1/1/2022 that fully vest on the first anniversary of the date of grant, subject to continued service as a director.

Read SEC document
August 10, 2021 Filed Aug 11, 2021 20:09 UTC COVETRUS, INC. CVET · Entity 123087 PurchaseCommon Stock 5,000 $23.24 $116,200.00
Disclosure

SEC source: 0001752836-21-000236 · wf-form4_162871252039507.xml · nonDerivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · price: Price reported constitutes the average weighted price of shares purchased. Shares were purchased at varying prices in the range of $23.05 - $23.37. The Reporting Person hereby undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.

Read SEC document
July 01, 2021 Filed Jul 6, 2021 20:03 UTC COVETRUS, INC. CVET · Entity 123087 GrantRestricted Stock Units · Derivative 8,275 $0.00 $0.00
Disclosure

SEC source: 0001752836-21-000213 · wf-form4_162560179895275.xml · derivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,275

Underlying: Common Stock · 8,275 shares

Expires 2022-07-01

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.

F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date.

Read SEC document
January 01, 2021 Filed Jan 5, 2021 00:31 UTC Apellis Pharmaceuticals, Inc. APLS · Entity 47322 GrantStock Option (Right to Buy) · Derivative 27,600 $0.00 Strike: $57.20 $0.00
Disclosure

SEC source: 0001127602-21-000261 · form4.xml · derivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,600

Underlying: Common Stock · 27,600 shares

Expires 2030-12-31

F1 · derivative.exercise_date: This option was granted on 01/01/2021. The option vests quarterly over 1 year on the last day of each quarter from grant date.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:40 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 21,289 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126315 · a4.xml · derivative · entry 4

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,289 shares

Expires not disclosed

F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:40 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 9,452 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126315 · a4.xml · derivative · entry 3

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,452 shares

Expires not disclosed

F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:40 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerStock Option (Right to Buy) · Derivative 6,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126315 · a4.xml · derivative · entry 2

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Read SEC document
November 16, 2020 Filed Nov 17, 2020 15:40 UTC AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 Disposition to issuerCommon Stock 14,676 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-20-126315 · a4.xml · nonDerivative · entry 1

FONTEYNE PAUL R. · CIK 0001727550 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.